Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01185 (
vasopressin
)
23,126
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The stainless steel cannula method was applied to isolated and perfused canine basilar arteries to examine the role of endothelium in the responses to intraluminal vasoactive substances. After intraluminal treatment with saponin to remove the endothelium, the monophasic constrictions to potassium chloride and prostaglandin F2 alpha were potentiated, while those to phenylephrine (alpha 1-adrenoceptor agonist) and 5-hydroxytryptamine were not changed. Xylazine (alpha 2-adrenoceptor agonist) and acetylcholine induced a constriction preceded by a small dilation in controls. The response to xylazine was not modified, while the constriction to acetylcholine was augmented after endothelium removal. Bradykinin, substance P and
vasopressin
caused a dilation in lower doses, and a dilation followed by a secondary constriction in higher doses in controls. The dilations to these peptides were reduced and the constrictions were enhanced after endothelial removal. Adenosine triphosphate produced a biphasic response, i.e., a dilation followed by a constriction, which was occasionally preceded by a small constriction in higher doses, and only the dilation in lower doses was attenuated. The monophasic dilation to adenosine was potentiated, while the papaverine-induced dilation was not influenced by endothelial removal. After extraluminal treatment with oxyhemoglobin, the dilations to calcium ionophore A23187 and thimerosal were attenuated, while the constriction to acetylcholine was enhanced. The dilations to substance P and
vasopressin
were depressed, and the constrictions were potentiated. The monophasic dilation to sodium nitroprusside was augmented, while that to papaverine was not changed. These results suggest that the endothelium may play important roles not only in producing endothelium-derived relaxing factors but also in modulating the calcium influx into the smooth muscle cells. The mechanisms of altered responsiveness might be implicated in cerebral vasospasm following
subarachnoid hemorrhage
.
...
PMID:Effects of endothelium removal by saponin and of oxyhemoglobin on canine cerebrovascular responses. 783 71
The relationship between plasma atrial natriuretic peptide (ANP) and
antidiuretic hormone
(
ADH
) both of which show high values after
subarachnoid hemorrhage
and cerebral vasospasm was studied. The subjects were 23 patients who were admitted because of aneurysmal
subarachnoid hemorrhage
during three years from March, 1989 to March, 1992 and in whom plasma ANP and
ADH
levels could be determined over time. Cerebral vasospasm was evaluated by the finding of cerebral angiography, clinical symptoms, and presence or not of low density areas on CT. Hyponatremia was defined as the serum sodium level of 130 mEq/l or less for two days or more. Angiographical vasospasm was found in 17 patients (85%), symptomatic vasospasm in 15 patients (65.2%), low density areas on CT in 9 patients (40.9%) and hyponatremia in 8 patients (34.8%). Symptomatic vasospasm was noted in 7 of the 8 patients (87.5%) with hyponatremia, low density areas on CT in 4 patients (50%), the detection rate being high. The plasma ANP and
ADH
levels were 76.7 +/- 32.1 pg/ml and 2.2 +/- 0.7 pg/ml respectively in the patients with symptomatic vasospasm against 38.3 +/- 21.3 pg/ml and 2.4 +/- 0.6 pg/ml respectively without symptomatic vasospasm, the plasma ANP level being significantly high in the patients with symptomatic vasospasm (p < 0.01). The plasma ANP and
ADH
were 71.2 +/- 33.8 pg/ml and 2.0 +/- 1.1 pg/ml respectively in the patients with low density areas on CT against 51.2 +/- 31.3 pg/ml and 1.8 +/- 0.5 pg/ml respectively without low density areas on CT.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[A study of plasma atrial natriuretic peptide, antidiuretic hormone and cerebral vasospasms in patients with aneurysmal subarachnoid hemorrhage]. 834 95
To determine how
vasopressin
affects the vascular tone of the smaller cerebral arterioles, we carried out an in vitro study of isolated and cannulated intracerebral arterioles of rats. We found that increasing concentrations of
vasopressin
induced a triphasic response of vasodilation (10(-12)-10(-11) M), vasoconstriction (10(-10)-10(-8) M), and vasodilation stabilizing to control diameter (10(-7)-10(-6) M) and that the maximum constriction was twice the maximum dilation in these smaller arterioles [21.2 +/- 13.1% (mean +/- SD) decrease in diameter vs. 11.2 +/- 5.7% increased]. Pretreatment of the arterioles with NG-monomethyl-L-arginine (10(-4) M), a specific inhibitor of endothelium-derived relaxing factor, abolished the
vasopressin
-induced vasodilation and significantly increased the vasoconstriction. These results suggest that these arterioles were maintained in a dilated state by an endothelium-derived relaxing factor activated by
vasopressin
. Both vasodilation and vasoconstriction were found to be mediated through
vasopressin
V1 receptors in a study of arterioles pretreated with d(CH2)5Tyr(Me)arginine vasopressin (10(-6) M), a
vasopressin
V1 receptor antagonist. These results support the hypothesis that
vasopressin
may constrict smaller cerebral arterioles while simultaneously dilating larger cerebral arteries. Our results also suggest that
vasopressin
may aggravate cerebral ischemia in pathological conditions, such as
subarachnoid hemorrhage
, when the arteriolar response to
vasopressin
shifts from vasodilation to vasoconstriction due to increased
vasopressin
levels in plasma and CSF and impaired endothelium-derived relaxation.
...
PMID:Triphasic response of rat intracerebral arterioles to increasing concentrations of vasopressin in vitro. 843 23
Hyponatremia frequently complicates the clinical course for patients with aneurysmal
subarachnoid hemorrhage
(
SAH
). Although commonly attributed to the syndrome of inappropriate
antidiuretic hormone
(SIADH), emerging evidence suggests a range of pathological conditions may produce the abnormality. Effective management requires an approach to data collection which avoids suppositions about etiology, as incorrect assumptions may result in selection of interventions leading to further clinical deterioration. Adherence to comprehensive monitoring and management protocols ensures rapid detection and efficient management of this common problem after
SAH
.
...
PMID:Hyponatremia after aneurysmal subarachnoid hemorrhage. 847 60
The authors report the frequency, characteristic clinical symptoms, laboratory alterations and diagnostic criteria of the syndrome of inappropriate secretion of
antidiuretic hormone
(SIADH) after
subarachnoid haemorrhage
. The data on 290 patients with
subarachnoid haemorrhage
(
SAH
) during a period of years at the Division of Neurosurgery, University Medical School, Szeged, are analysed. Twenty-seven (9.3%) patients developed SIADH. Thirteen (4.5%) patients had severe and 14 (4.8%) had mild SIADH. The problems of the treatment are discussed in detail and the different therapeutic methods are listed: NaCl infusion, water withdrawal and administration of Dilantin, diuretics, mineralocorticosteroids, lithium and demeclocycline. The undesirable side-effects observed accompanying various therapeutic regimen are analysed. The introduction of V2 antagonists into clinical practice appears to be a most perspective procedure. For study of the pathogenesis of SIADH following
SAH
, the possibility of treatment with V2 antagonists on an experimental model of
SAH
in rat was created. A significant water retention and increases in brain water and sodium content were observed in rats with
SAH
. Plasma AVP levels were also elevated after
SAH
. AVP plays an important role in the development of antidiuresis following water loading and disturbance of the brain water and electrolyte balance after
SAH
. Water retention and the higher brain water and sodium accumulation could be totally prevented by administration of a V2 antagonist. These results demonstrate that cerebral oedema generated by artificial cerebral bleeding in rats is significantly reduced following the administration of a highly specific V2 antagonist, suggesting a new approach to the treatment of SIADH.
...
PMID:Cerebral oedema after subarachnoid haemorrhage. Pathogenetic significance of vasopressin. 874 54
To prevent symptomatic cerebral vasospasm, we have used hypervolaemia (HV) or volume expansion in patients with aneurysmal
subarachnoid haemorrhage
(
SAH
) in recent years. In these patients we could not perform effective fluid and sodium (Na) replacement because of rapid and overwhelming water and Na loss. Although this phenomenon is characteristic under hypervolaemic states, we regard it important to elucidate the mechanism underlying initiation of vasospasm after aneurysmal
SAH
. Patients with aneurysmal
SAH
, operated on within 24 hours of onset, were analysed prospectively. We selected 17 patients in good pre-operative condition. Intravascular volume expansion was accomplished with plasma fractionate or albumin and crystalloid solutions in all patients. We divided the 17 patients into two groups; symptomatic spasm group (S-group) consisting of 4 cases developing transient ischaemic symptoms and non-symptomatic spasm group (NS-group) consisting of 13 cases. In S-group, rapid and marked natriuresis developed characteristically before the onset of ischaemic symptoms. The differences in daily Na balance between the two groups were significant on the 3rd and 5th days (p < 0.05). The mean cumulative Na balance in S-group during the 10 days of the study (-375 +/- 159 mEg) was higher than that of NS-group (-24.4 +/- 225 mEq) (p < 0.05). Rapid natriuresis preceded the development of ischaemic symptoms, and was important as a trigger for symptomatic vasospasm after
SAH
. We considered that hormonal disorders were implicated in this phenomenon, and atrial natriuretic peptide (ANP),
antidiuretic hormone
(
ADH
), renin, and aldosterone were each measured three times during the period, with no significant differences, found between the two groups. It was speculated that another potent natriuretic factor, similar to ANP, induced a rapid selective natriuresis resulting in symptomatic vasospasm.
...
PMID:Rapid natriuresis and preventive hypervolaemia for symptomatic vasospasm after subarachnoid haemorrhage. 889 Sep 92
Hyponatremia is a common complication after
subarachnoid hemorrhage
(
SAH
). Although the mechanism of hyponatremia is still controversial, cerebral salt-wasting syndrome (CSNS) is currently regarded as being more responsible than the syndrome of inappropriate secretion of
antidiuretic hormone
(SIADH). The aim of our study was to assess the plasma volume status of a patient with hyponatremia following
subarachnoid hemorrhage
. In doing this it may be possible to indirectly differentiate its pathogenesis. Fifty patients with
SAH
were studied. Twenty patients demonstrated hyponatremia (serum sodium < 135 mEq/L) during day 7 to 13 after
subarachnoid hemorrhage
. Patients with hyponatremia were categorized on the basis of their daily body weight, and central venous pressure. Group A consisted of patients with hypovolemia (16 patients), with the onset time of hyponatremia being day 7 to 9. Group B included those with hypervolemia (4 patients); hyponatremia was observed during day 10 to 11 and was corrected in all patients within 72 hours after induction of fluid restriction. Our findings suggest that hyponatremia following
subarachnoid hemorrhage
usually occurs due to CSWS, although SIADH remains as a minor pathogenesis. We conclude that the combination of daily body weight and CVP measurements is a simple and practical method to distinguish promptly SIADH from CSWS.
...
PMID:[Differential diagnosis of hyponatremia following subarachnoid hemorrhage]. 963 2
Diabetes insipidus (DI) is an uncommon but important complication in the neurosurgical population. This retrospective study aimed to determine the incidence, profile and outcome of patients admitted to an 18-bedded neurosurgical intensive care unit who developed DI. The overall incidence was 3.7% (29/792 admissions). Aetiologies included
subarachnoid haemorrhage
(12/29), severe head injury (11/29), post-surgical excision of craniopharyngioma or pituitary adenoma (5/29) and acute haemorrhagic stroke (1/29). All patients were treated with a regime of fluid replacement, electrolyte correction, parenteral or intranasal desmopressin (DDAVP), or parenteral pitressin. Overall mortality was 72.4%. There were no deaths in the patients who underwent excision of tumours. Complications included acute pulmonary oedema, hypernatremia and hypokalaemia. The development of DI was found to be associated with impending brain death and mortality in the majority of patients with
subarachnoid haemorrhage
and severe head injury. However, careful diagnosis and management of DI after hypothalamo-
neurohypophyseal
surgery did not result in any permanent neurological sequelae.
...
PMID:Diabetes insipidus in neurosurgical patients. 977 76
The effects of the non-peptide vasopressin V2 receptor antagonist, 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrah ydro-1 H-benzazepine hydrochloride (OPC-31260) on the cerebral oedema induced by
subarachnoid haemorrhage
were studied in rats.
Subarachnoid haemorrhage
induced significant water retention after water loading, increased the brain content of water and Na+ and increased plasma
vasopressin
levels. The water retention and brain water and Na+ accumulation were prevented by OPC-31260 administration, but the plasma
vasopressin
levels were further enhanced by OPC-31260. These results demonstrate the important role of
vasopressin
in the development of antidiuresis and disturbances in brain water and electrolyte balance in response to
subarachnoid haemorrhage
. The
subarachnoid haemorrhage
-induced cerebral oedema was significantly reduced following oral OPC-31260 administration. The protective mechanism exerted by OPC-31260 stems from its influence on renal tubular function: it blocks the renal
vasopressin
V2 receptors. These observations might suggest a new, effective approach to the treatment of
subarachnoid haemorrhage
-induced cerebral oedema in humans.
...
PMID:Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage. 993 13
We used the nested polymerase chain reaction (PCR) assays developed previously to detect and identify Mycobacterium tuberculosis (M. tuberculosis) in the cerebrospinal fluid (CSF) samples from patients with suspected tuberculous meningitis and non-tuberculous patients. Our nested PCR assays target the multi-copy IS6110 insertion element and the single-copy mtp40 genomic DNA of M. tuberculosis. These assays, when used in combination, allowed us to detect a very low number of M. tuberculosis in the CSF samples, which otherwise would be undetectable by the culture method, and to distinguish M. tuberculosis from M. bovis. We applied these nested PCR assays to analyze eleven CSF samples. Among these, five of them were from patients with suspected tuberculous meningitis but all except one were culture negative. Our results of PCR assays show that three of these five are M. tuberculosis positive, one of which is M. bovis positive, and only one is M. tuberculosis negative. The other six CSF samples were from the clinically diagnosed non-tuberculous patients. Surprisingly, two of these so called non-tuberculous patients, a
subarachnoid hemorrhage
(
SAH
) and the syndrome of inappropriate
antidiuretic hormone
secretion (SIADH), were shown M. tuberculosis positive. This finding supports a long-standing argument that tuberculous meningitis is one of the causes of these neurological diseases. These nested PCR assays thus provide the neurologists with an important adjunct, in addition to the patient's clinical presentation and laboratory data, for the diagnosis of tuberculous meningitis.
...
PMID:Detection and identification of Mycobacterium tuberculosis by nested PCR assays in cerebrospinal fluid samples from patients with suspected tuberculous meningitis. 1051 64
<< Previous
1
2
3
4
5
6
7
8
Next >>